| scholarly article | Q13442814 |
| P50 | author | Michael A Sheard | Q57035794 |
| Richard B Lock | Q61292565 | ||
| C P Reynolds | Q67015887 | ||
| Min H Kang | Q73476305 | ||
| Barbara Szymanska | Q117258545 | ||
| Urszula Wilczynska-Kalak | Q117258547 | ||
| P2093 | author name string | Yun Hee Kang | |
| Theresa M Harned | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dexamethasone | Q422252 |
| lymphoblastic leukemia | Q18553852 | ||
| P304 | page(s) | 2057-2066 | |
| P577 | publication date | 2007-05-29 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo | |
| P478 | volume | 110 |
| Q40369034 | 2-deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines |
| Q38640917 | ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development |
| Q34533975 | ABT-737 induces Bim expression via JNK signaling pathway and its effect on the radiation sensitivity of HeLa cells |
| Q36425600 | ABT-737 synergizes with Bortezomib to kill melanoma cells |
| Q39280369 | ABT-737 synergizes with arsenic trioxide to induce apoptosis of gastric carcinoma cells in vitro and in vivo |
| Q39879308 | ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway |
| Q42094231 | ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells |
| Q41847989 | Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. |
| Q39956386 | Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins |
| Q39920726 | BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. |
| Q24655483 | BH3 mimetics to improve cancer therapy; mechanisms and examples |
| Q37797387 | BH3-Only Proteins and Their Effects on Cancer |
| Q37629756 | BH3-only proteins: the death-puppeteer's wires |
| Q26823996 | Bcl-2 antagonists: a proof of concept for CLL therapy |
| Q24635408 | Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy |
| Q90782133 | CD9 blockade suppresses disease progression of high-risk pediatric B-cell precursor acute lymphoblastic leukemia and enhances chemosensitivity |
| Q38982534 | Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines. |
| Q34135333 | Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts |
| Q35331086 | Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model |
| Q58751919 | Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia |
| Q36544778 | Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia |
| Q33864314 | Combination of BCL11A siRNA with vincristine increases the apoptosis of SUDHL6 cells |
| Q37786022 | Drugs targeting Bcl-2 family members as an emerging strategy in cancer |
| Q36610528 | How to target apoptosis signaling pathways for the treatment of pediatric cancers |
| Q92669135 | In vitro effect of curcumin in combination with chemotherapy drugs in Ph+ acute lymphoblastic leukemia cells |
| Q36970689 | In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas |
| Q36541458 | Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review |
| Q42410120 | Interactions of pro-apoptotic BH3 proteins with anti-apoptotic Bcl-2 family proteins measured in live MCF-7 cells using FLIM FRET. |
| Q36426910 | MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. |
| Q90712375 | Mechanisms of cell death induced by arginase and asparaginase in precursor B-cell lymphoblasts |
| Q37341018 | Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis |
| Q37376084 | Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo |
| Q36602853 | MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies |
| Q39168078 | Microarray determination of Bcl-2 family protein inhibition sensitivity in breast cancer cells |
| Q36619787 | Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo |
| Q41733073 | Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse |
| Q33801384 | Personalising pancreas cancer treatment: When tissue is the issue |
| Q38061500 | Pharmacogenomic considerations of xenograft mouse models of acute leukemia |
| Q34221738 | Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. |
| Q37868449 | Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes |
| Q37301312 | Relapsed acute lymphoblastic leukemia: current status and future opportunities |
| Q35779325 | Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737 |
| Q38939084 | Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc |
| Q34323880 | Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma |
| Q39774066 | Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol |
| Q36989223 | Targeted drug discovery for pediatric leukemia |
| Q34115304 | Targeting mitochondria for cancer therapy |
| Q91137768 | Targeting mitochondria in cancer: current concepts and immunotherapy approaches |
| Q39832788 | Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. |
| Q37120213 | Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? |
| Q39466656 | The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells |
| Q38439738 | The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias |
| Q64111708 | The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome |
| Q34448863 | The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma |
| Q37431491 | Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics |
| Q37738597 | Update on developmental therapeutics for acute lymphoblastic leukemia |
| Q37092954 | Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737. |
| Q33758493 | Why anti-Bcl-2 clinical trials fail: a solution |
Search more.